2771 related articles for article (PubMed ID: 28768855)
21. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.
Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X
Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985
[TBL] [Abstract][Full Text] [Related]
22. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
23. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
24. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
25. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
26. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.
Rajão DS; Chen H; Perez DR; Sandbulte MR; Gauger PC; Loving CL; Shanks GD; Vincent A
J Gen Virol; 2016 Jul; 97(7):1489-1499. PubMed ID: 27031847
[TBL] [Abstract][Full Text] [Related]
27. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
28. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
[TBL] [Abstract][Full Text] [Related]
29. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses.
Reneer ZB; Skarlupka AL; Jamieson PJ; Ross TM
mSphere; 2021 Mar; 6(2):. PubMed ID: 33692193
[TBL] [Abstract][Full Text] [Related]
30. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
31. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.
Pappas C; Matsuoka Y; Swayne DE; Donis RO
Clin Vaccine Immunol; 2007 Nov; 14(11):1425-32. PubMed ID: 17913860
[TBL] [Abstract][Full Text] [Related]
33. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
34. Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice.
Wang Y; Zhang Y; Wu J; Lin Y; Wu Z; Wei Y; Wei X; Qin J; Xue C; Liu GD; Cao Y
Virus Res; 2017 Oct; 242():16-23. PubMed ID: 28912070
[TBL] [Abstract][Full Text] [Related]
35. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice.
Tang LH; Lim JH; Kuah LF; Lau YF
Vaccine; 2014 Sep; 32(42):5375-8. PubMed ID: 25130540
[TBL] [Abstract][Full Text] [Related]
36. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
37. A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.
Powell TJ; Rijal P; McEwen-Smith RM; Byun H; Hardwick M; Schimanski LM; Huang KA; Daniels RS; Townsend ARM
J Gen Virol; 2019 Mar; 100(3):431-445. PubMed ID: 30714896
[TBL] [Abstract][Full Text] [Related]
38. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
[TBL] [Abstract][Full Text] [Related]
39. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
Chen Z; Baz M; Lu J; Paskel M; Santos C; Subbarao K; Jin H; Matsuoka Y
J Virol; 2014 Jun; 88(12):7016-23. PubMed ID: 24719414
[TBL] [Abstract][Full Text] [Related]
40. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.
Rajesh Kumar S; Syed Khader SM; Kiener TK; Szyporta M; Kwang J
PLoS One; 2013; 8(6):e63856. PubMed ID: 23762234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
